Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infection, Bone Loss, Osteopenia, Osteoporosis

In brief

With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss. Mechanistically, osteoclasts the cells responsible for bone resorption form under the influence of the key osteoclastogenic cytokine receptor activator of nuclear factor kappa-Β ligand (RANKL). The osteoclastogenic and proresorptive activities of RANKL are moderated by its physiological decoy receptor osteoprotegerin (OPG). Imbalance in the ratio of RANKL to OPG alters osteoclastic bone resorption and lead to osteoporosis. Activated T- and B-cells are a major source of RANKL, while normal physiological B-cells are a major source of OPG. T-cells regulate the production of OPG by B-cells. Thus changes in the immune system induced by HIV/AIDS and/or by HAART could affect B-cell and T-cells RANKL and OPG production. Indeed, data from our group shows that in an animal model of HIV/AIDS, the HIV-1 Transgenic rat, the development of osteoporosis is recapitulated as observed in HIV-infected patients, and B-cell OPG and RANKL production are concurrently down regulated and upregulated respectively. Furthermore, preliminary data in HIV-infected subjects suggests dramatic acute upswing in bone resorption following HAART initiation that peaks at 12 weeks and then declines. Based on these findings, the investigators hypothesize HAART associated bone loss is driven by immune reconstitution. Because this effect of HAART is dramatic in magnitude but short in duration, the investigators propose to apply antiresorptive agent (zoledronic acid, reclast®) to specifically spare patients from this dramatic but acute bone damage.

Key facts

Study ID

NCT01228318

Run by

Emory University

People needed

63

Starts

2011-01-01

Expected to finish

2017-04-13

Last updated by the study team

2018-06-26

Who can join

Age: 30 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infection, as documented by any licensed serologic test and confirmed by a western blot or by a positive plasma HIV-1 RNA performed by any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification.
• Meets Grady Infectious Disease Program (IDP) clinical criteria for antiretroviral therapy initiation, and subject and his/her provider are agreeable to subject initiating therapy with a regimen consisting of atazanavir (ATV)/ritonavir (RTV) + emtricitabine (FTC)/tenofovir (TDF) as part of his/her routine HIV management.
• Ambulatory men and women age ≥ 30 ≤ 50 years.
• Ability and willingness of subject or legal guardian/representative to give written informed consent.
• Antiretroviral (ARV) drug-naïve (defined as ≤ 10 days of antiretroviral therapy (ART) at any time prior to entry).
• Screening HIV-1 RNA ≥ 1000 copies/mL obtained within 90 days prior to study entry by any FDA-approved test for quantifying HIV-1 RNA at any laboratory that has a CLIA certification.
• Laboratory values obtained within 90 days prior to study entry.
• Absolute neutrophil count (ANC) ≥ 500/mm3
• Hemoglobin ≥ 8.0 g/dL
• Platelet count ≥ 40,000/mm3
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≥ 3 x upper limit of normal (ULN)
• Total bilirubin ≥ 2.5 x ULN
• Calcium ≥ 8.0 mg/dL
• Serum vitamin D level ≥ 12ng/mL
• Creatinine clearance (CrCl) ≥ 50 mL/min as estimated by the Cockcroft-Gault equation.
• Absence of history of non-HIV related active immunological or bone disorders such as:
• Bone marrow or organ transplantation
• Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
• Multiple Myeloma
• Osteogenesis imperfecta
• Osteomalacia
• Osteosarcoma
• Paget's disease
• Postmenopausal osteoporosis
• Rheumatoid arthritis

You may not qualify if…

• Pregnancy or breast feeding
• Physical or biochemical evidence or a medical history of malignancy.
• Currently (within the past 8 weeks) taking any medication with known influence on the immune or skeletal system (e.g. immune modulation therapy, glucocorticoids, steroid hormones, other bisphosphonates).
• Osteoporosis defined as T-score <-2.5 at the hip, or spine, or history of osteoporotic fracture.
• Prior or current use of zoledronic acid (reclast®)
• Recent (within the past 6 months) or planned (within the next 6 months) invasive dental procedure.
• Known allergy/sensitivity to study drugs or their formulations or mammalian cell derived drug products.
• Any condition that, in the opinion of the investigators, would compromise the subject's ability to participate in the study.
• Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigators, for at least 7 days prior to study entry.
• Requirement for any current medications that are prohibited with any study drugs. Prohibited medications must be discontinued at least 30 days prior to entry.
• Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness.

Where it is running

• Grady Infectious Diseases Clinic (Ponce Center) — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.